PEP-Therapy

Develops innovative peptides as targeted therapies in oncology. Its lead drug candidate, PEP-010, is a pro-apoptotic peptide that has demonstrated anti-tumoranti-tumour efficacy in several preclinical models, as well as good tolerability and encouraging early signals of anti-tumoranti-tumour activity in Phase Ia clinical trials. The Phase Ib trial is currently underway, focusing on platinum-resistant ovarian cancer and pancreatic adenocarcinoma.